The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal Phase 3 PURPOSE 2 ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) on November 25 and set a price target ...

Considering “health equity aspects”, Moupali Das highlighted the historic underrepresentation of disproportionately affected ...

A vaccination with the drug lenacapavir offers an effective protection against a HIV infection, according to newly published ...

Lead PURPOSE researcher Moupali Das, Vice President, Clinical Development, HIV Prevention & Pediatrics, designed the PURPOSE ...

This week's Richland County Girls Basketball Power Poll didn't change a whole lot, but there was some movement.

Casita Feliz, a nonprofit serving the Latino LGBTQ+ community in Fresno, recently celebrated its one-year anniversary ...

Lenacapavir, an injectable PrEP taken twice a year, demonstrated 96% efficacy in preventing HIV infections in a global Phase ...

Did you ever hear the saying “You can’t go home again?” Well, I did, this fall. I went to my old home in the Bartlettboro Neighborhood of East Stoneham. I was anxious to know if the “Balm of Gilead” ...

In addition, we kept open the possibility that the ETF will continue to rise and could reach around 108.45. To see how we ...